skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502)

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2]; ;  [3];  [4];  [5];  [6]
  1. Univ. of Louisville School of Medicine, KY (United States)
  2. RTOG Headquarters, Philadelphia, PA (United States)
  3. Washington Univ. School of Medicine, St. Louis, MO (United States)
  4. Radiation Oncology Center, Sacramento, CA (United States)
  5. Univ. of Rochester Medical Center, NY (United States)
  6. New York Univ., New York, NY (United States)

The purpose was to determine late complication incidence for pelvic palliation using accelerated multiple daily fraction radiation [Radiation Therapy Oncology Group (RTOG) 8502]. None of the patients with < 30 Gy (less than three courses) developed late toxicity. A total of 11/193 (6%) developed Grade 3+ late toxicity (nine Grade 3, on Grade 4, one Grade 5). Actuarial analysis of complication rate by survival time for Grades 3, 4, and 5 shows a cumulative incidence for complications after 6 months that plateaus at 6.9% by 18 months. The cumulative incidence for Grades 4 and 5 is 2.0% by 12 months. The difference in late effect for the 2-week rest vs. 4-week rest was not statistically different (p = .47). Patient factors evaluated for increased risk of late complications included prior surgeries, age, sex, KPS and primary. None were found to have significant statistical correlations with late effects. The crude late complications rate is 6%. Actuarial analysis using cumulative incidence shows 6.9% by 18 months. This represents a significant decrease in late complications from 49% seen with higher dose per fraction (10 Gy {times} 3) piloted by Radiation Therapy Oncology Group (7905) for a similar group of patients. Long-term analysis of late complication indicates this schedule can be used in the pelvis with relatively low incidence of complication. This schedule has significant logistic benefits and has been shown to produce good tumor regression and excellent palliation of symptoms. 14 refs., 4 figs., 4 tabs.

Sponsoring Organization:
USDOE
OSTI ID:
68506
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 29, Issue 5; Other Information: PBD: 30 Jul 1994
Country of Publication:
United States
Language:
English

Similar Records

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study
Journal Article · Wed Mar 15 00:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:68506

Phase I Trial of Pelvic Nodal Dose Escalation With Hypofractionated IMRT for High-Risk Prostate Cancer
Journal Article · Sun Jan 01 00:00:00 EST 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:68506

High-dose-rate brachytherapy in uterine cervical carcinoma
Journal Article · Sun May 01 00:00:00 EDT 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:68506